Journal
NANOMEDICINE
Volume 10, Issue 18, Pages 2881-2891Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nnm.15.125
Keywords
functional protein aggregates; nanobiotechnology; nanomedicine; nanoparticles; recombinant protein
Funding
- INIA [RTA2012-00028-C02-02]
- MINECO [BIO2013-41019-P]
- Agencia de Gestio d'Ajuts Universitaris i de Recerca [2014SGR-132]
- Centro de Investigacion Biomedica en Red (CIBER) de Bioingenieria, Biomateriales y Nanomedicina
- Instituto de Salud Carlos III
- European Regional Development Fund
- Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria (DOC-INIA)
- Asociacion Espanola Contra el Cancer (AECC)
- ICREA ACADEMIA Award
Ask authors/readers for more resources
An increasing number of both prokaryotic and eukaryotic cell types are being adapted as platforms for recombinant protein production. The overproduction of proteins in such expression systems leads to the formation of insoluble protein-based aggregates. Although these protein clusters have been poorly studied in most of the eukaryotic systems, aggregates formed in E. coli, named inclusion bodies (IBs), have been deeply characterized in the last decades. Contrary to the general belief, an important fraction of the protein embedded in IB is functional, showing promise in biocatalysis, regenerative medicine and cell therapy. Thus, the exploration of all these functional protein clusters would largely expand their potential in both pharma and biotech industry.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available